NCT07104916View on ClinicalTrials.gov

Mindfulness-based Psilocybin Therapy for PTSD

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

December 31, 2029

Conditions
Post Traumatic Stress DisorderDepression - Major Depressive Disorder
Interventions
COMBINATION_PRODUCT

Psilocybin + MBCT therapy

The experimental arm has psilocybin with support and MBCT sessions.

COMBINATION_PRODUCT

Active Comparator: Psilocybin with Support Only

The active comparator has psilocybin with support only.

All Listed Sponsors
lead

Anthony P King

OTHER

NCT07104916 - Mindfulness-based Psilocybin Therapy for PTSD | Biotech Hunter | Biotech Hunter